相关实验视频

Updated: Jun 15, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

超越胰岛素:GLP-1在帕金森病中的有趣作用

Aanchal Verma¹, Ahsas Goyal¹

¹Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.

European journal of pharmacology

|August 25, 2024

概括

葡萄糖类1 (GLP-1) 受体激活剂在治疗帕金森病 (PD) 方面表现有前途. 这些药物提供神经保护和减少炎症,可能减缓PD患者的神经退行.

科学领域:

神经科学是一个神经科学.
内分泌学在内分泌学.
药理学药理学是指药理学的学科.

背景情况:

帕金森病 (PD) 是一种进展性神经退行性疾病,治疗选择有限.
2型糖尿病 (T2DM) 可能会增加PD的风险并加剧其进展.
葡萄糖类1 (GLP-1) 是一种通过GLP-1受体 (GLP-1R) 激活具有神经保护和抗炎作用的激素.

研究的目的:

审查GLP-1受体 (GLP-1R) 激动剂作为帕金森病 (PD) 治疗策略的潜力.
在PD的背景下探索GLP-1R激动剂的神经保护机制.
检查临床前和临床证据支持GLP-1R激动剂用于PD治疗.

主要方法:

临床前和临床研究的文献综述.
在神经退行性模型中分析GLP-1R激动剂作用的数据.
检查结合的神经保护益处和机制.

主要成果:

在各种临床前模型中,GLP-1R激动剂表现出神经营养,抗炎和神经保护作用.
一些GLP-1R激动剂已被批准用于T2DM管理,这表明了有利的安全性.
有证据表明GLP-1R激动剂可以减轻PD症状和神经退行.

结论:

GLP-1R激动剂代表了帕金森病的有希望的治疗途径.
需要对其神经保护机制和PD临床疗效进行进一步的研究.
GLP-1在代谢调节和神经保护中的双重作用为PD提供了一个独特的治疗机会.

关键词:

它是GLP-1受体激动剂.类似葡萄糖的1 类似葡萄糖的1 神经退行发生神经退行.神经炎症是一种神经炎症.氧化应激是一种氧化应激.这是帕金森氏症.

更多相关视频

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

Primary Culture of Mouse Dopaminergic Neurons

Primary Culture of Mouse Dopaminergic Neurons

Published on: September 8, 2014

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Hormones Regulating Blood Glucose

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...